{"title":"一种新型抗hiv药物。","authors":"","doi":"10.1001/jama.282.21.1994","DOIUrl":null,"url":null,"abstract":"A new class of anti-HIV drugs has entered the treatment arena. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) interfere with infected cells and suppress their ability to replicate. Delaviradine (Rescriptor) and nevirapine (Viramune) are described, including drug interactions, trial results, and the potential for resistance.","PeriodicalId":23328,"journal":{"name":"Treatment review","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1996-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A new class of anti-HIV drugs.\",\"authors\":\"\",\"doi\":\"10.1001/jama.282.21.1994\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"A new class of anti-HIV drugs has entered the treatment arena. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) interfere with infected cells and suppress their ability to replicate. Delaviradine (Rescriptor) and nevirapine (Viramune) are described, including drug interactions, trial results, and the potential for resistance.\",\"PeriodicalId\":23328,\"journal\":{\"name\":\"Treatment review\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1996-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Treatment review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1001/jama.282.21.1994\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Treatment review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jama.282.21.1994","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A new class of anti-HIV drugs has entered the treatment arena. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) interfere with infected cells and suppress their ability to replicate. Delaviradine (Rescriptor) and nevirapine (Viramune) are described, including drug interactions, trial results, and the potential for resistance.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
